Also visit: Campus Mixxer | Boxxet
 

SciClone Pharmaceuticals, Inc.: SciClone Completes Enrollment Ahead of Schedule in Phase 2 Trial for RP101 in Late-Stage Pancreatic Cancer Patients external link

Market Wire | Mon, Mar 9

Market Wire is the #2 Blogger for Pancreatic cancer

FOSTER CITY, CA (MARKET WIRE) SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that enrollment has been completed ahead of schedule in the Company's phase 2 clinical trial for RP101 in patients with late-stage pancreatic cancer. Results from a previous phase 1 study in 22...

[Read original...]

Try These Related Topics

 
 
 

Do you publish a blog? If so, consider joining the Boxxet Network and see your great content showcased and rewarded! Learn more...

©2009 Boxxet, Inc. | Contact | Privacy Policy | Terms of Service
Page updated Mon, Jan 18.